Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

US Patent 10983128 · Granted Apr 20, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antibodies binding to ILT42025
Antibodies against TIM3 and uses thereof2025
Antibodies binding to VISTA at acidic pH2025
Antibodies binding to VISTA at acidic pH2025
Antibodies binding to vista at acidic pH2024
Antibodies binding to vista at acidic pH2024
Antibodies against TIM3 and uses thereof2024
Anti-CD27 antibodies and uses thereof2024
Antibodies binding to vista at acidic pH2024
Antibodies binding to vista at acidic pH2024
Methods of treating HLA-E-expressing cancers by administering antibodies which b2024
Nucleic acid molecules encoding antibodies which bind natural killer cell inhibi2024